JP2019512542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512542A5 JP2019512542A5 JP2018567022A JP2018567022A JP2019512542A5 JP 2019512542 A5 JP2019512542 A5 JP 2019512542A5 JP 2018567022 A JP2018567022 A JP 2018567022A JP 2018567022 A JP2018567022 A JP 2018567022A JP 2019512542 A5 JP2019512542 A5 JP 2019512542A5
- Authority
- JP
- Japan
- Prior art keywords
- theta
- values
- xrpd pattern
- crystalline form
- characteristic peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 86
- 239000013078 crystal Substances 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 34
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims description 3
- 229940080277 cholesteryl sulfate Drugs 0.000 claims description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 3
- 150000003891 oxalate salts Chemical class 0.000 claims description 3
- 125000005490 tosylate group Chemical class 0.000 claims description 3
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003890 succinate salts Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307095P | 2016-03-11 | 2016-03-11 | |
| US62/307,095 | 2016-03-11 | ||
| PCT/US2017/021790 WO2017156403A1 (en) | 2016-03-11 | 2017-03-10 | Crystalline salt forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512542A JP2019512542A (ja) | 2019-05-16 |
| JP2019512542A5 true JP2019512542A5 (enExample) | 2020-03-26 |
| JP7038675B2 JP7038675B2 (ja) | 2022-03-18 |
Family
ID=59789873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567022A Active JP7038675B2 (ja) | 2016-03-11 | 2017-03-10 | 結晶塩形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10683326B2 (enExample) |
| EP (1) | EP3426675B1 (enExample) |
| JP (1) | JP7038675B2 (enExample) |
| CN (2) | CN109476700A (enExample) |
| CA (1) | CA3017359A1 (enExample) |
| WO (1) | WO2017156403A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3017359A1 (en) | 2016-03-11 | 2017-09-14 | Scott M. Duncan | Crystalline salt forms |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| IL277718B2 (en) * | 2018-04-02 | 2025-02-01 | Stealth Biotherapeutics Corp | Crystalline dipeptides used in the synthesis of almipretide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2085865T3 (es) | 1988-06-30 | 1996-06-16 | Astra Ab | Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean. |
| PT1599216E (pt) | 2003-02-04 | 2013-12-17 | Cornell Res Foundation Inc | Métodos de prevenção da transição de permeabilidade mitocondrial |
| US20120178762A1 (en) * | 2006-12-15 | 2012-07-12 | Warner Chilcott Company, Llc | Compositions of azimilide dihydrochloride |
| CN102573881A (zh) * | 2009-03-20 | 2012-07-11 | 通用医疗公司以马萨诸塞州通用医疗公司名义经营 | 预防和治疗烧伤损伤和继发性并发症的方法 |
| ES2660146T3 (es) * | 2009-04-29 | 2018-03-21 | Nerviano Medical Sciences S.R.L. | Sales del inhibidor de cdk |
| EP4302829B1 (en) * | 2009-08-24 | 2025-05-21 | Stealth BioTherapeutics Inc. | Peptide for use in preventing or treating macular degeneration |
| JP2013516425A (ja) * | 2009-12-31 | 2013-05-13 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 血管閉塞傷害の予防または治療方法 |
| EP2528934A4 (en) * | 2010-01-25 | 2013-08-21 | Univ Cornell | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
| EP3375449A1 (en) * | 2010-03-15 | 2018-09-19 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| WO2011156473A1 (en) | 2010-06-09 | 2011-12-15 | Abbott Laboratories | Crystalline forms of kinase inhibitors |
| EP3281634A1 (en) * | 2012-02-22 | 2018-02-14 | Stealth Peptides International, Inc. | Method and compositions for preventing or treating ophthalmic conditions |
| CA2916884C (en) * | 2013-03-01 | 2021-02-09 | Stealth Biotherapeutics Corp | Methods for the treatment of mitochondrial disease |
| JP2016539931A (ja) * | 2013-10-23 | 2016-12-22 | 株式会社カネカ | テトラペプチド化合物及びその製造方法 |
| ES2784325T3 (es) * | 2013-12-03 | 2020-09-24 | Amgen Inc | Formas cristalinas de sales farmacéuticamente aceptables de N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas |
| WO2016004067A1 (en) * | 2014-06-30 | 2016-01-07 | Stealth Biotherapeutics Corp | Aromatic-cationic peptide formulations, compositions and methods of use |
| EP3160985B1 (en) * | 2014-06-30 | 2021-07-28 | Flamma S.P.A. | Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide |
| US20170189429A1 (en) * | 2014-07-10 | 2017-07-06 | Rhode Island Hospital | Treating Arrhythmia with Mitochondrial-Targeted Antioxidants |
| CA2978905A1 (en) * | 2015-03-06 | 2016-09-15 | Stealth Biotherapeutics Corp | Processes for preparing pharmaceutically relevant peptides |
| CA3017359A1 (en) | 2016-03-11 | 2017-09-14 | Scott M. Duncan | Crystalline salt forms |
| EP3500286A4 (en) * | 2016-08-16 | 2020-03-25 | Stealth BioTherapeutics Corp | N-CARBOXYANHYDRIDE-BASED ELAMIPRETIDE SCALE SYNTHESIS |
| US11034724B2 (en) * | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) * | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| IL277718B2 (en) * | 2018-04-02 | 2025-02-01 | Stealth Biotherapeutics Corp | Crystalline dipeptides used in the synthesis of almipretide |
-
2017
- 2017-03-10 CA CA3017359A patent/CA3017359A1/en active Pending
- 2017-03-10 US US16/084,168 patent/US10683326B2/en active Active
- 2017-03-10 JP JP2018567022A patent/JP7038675B2/ja active Active
- 2017-03-10 EP EP17764188.3A patent/EP3426675B1/en active Active
- 2017-03-10 CN CN201780029335.8A patent/CN109476700A/zh active Pending
- 2017-03-10 CN CN202210620260.3A patent/CN115160402A/zh active Pending
- 2017-03-10 WO PCT/US2017/021790 patent/WO2017156403A1/en not_active Ceased
-
2020
- 2020-05-04 US US16/866,164 patent/US11555053B2/en active Active
-
2022
- 2022-12-02 US US18/074,151 patent/US12252553B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512542A5 (enExample) | ||
| JP2018024682A5 (enExample) | ||
| JP2014522388A5 (enExample) | ||
| JP2015527363A5 (enExample) | ||
| JP2013032389A5 (enExample) | ||
| JP2018024670A5 (enExample) | ||
| JP2021530565A5 (enExample) | ||
| JP2013049690A5 (enExample) | ||
| JP2017521436A5 (enExample) | ||
| WO2016016766A3 (en) | A process for the preparation of isavuconazonium or its salt thereof | |
| JP2017501141A5 (enExample) | ||
| JP2016000739A5 (enExample) | ||
| JP2009179634A5 (enExample) | ||
| WO2016038628A3 (en) | A process for preparing olodaterol and intermediates thereof | |
| JP2013520488A5 (enExample) | ||
| JP2019529481A5 (enExample) | ||
| JP2015518469A5 (enExample) | ||
| JP2013503145A5 (enExample) | ||
| JP2020502077A5 (enExample) | ||
| HRP20170023T1 (hr) | Kristalni oblik pemirolasta | |
| JP2015218351A5 (enExample) | ||
| JP2015514779A5 (enExample) | ||
| WO2016027283A3 (en) | A process for preparing indacaterol and salts thereof | |
| CN106604916A (zh) | 钾离子竞争性酸阻滞剂的晶型及其制备方法 | |
| JP2016520090A5 (enExample) |